Cas:356-02-5 33FTA manufacturer & supplier

We serve Chemical Name:33FTA CAS:356-02-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

33FTA

Chemical Name:33FTA
CAS.NO:356-02-5
Synonyms:33FTA;Hexanoic acid, 4,4,5,5,6,6,6-heptafluoro-;MFCD00077553;4,4,5,5,6,6,6-Heptafluorohexanoic acid
Molecular Formula:C6H5F7O2
Molecular Weight:242.092
HS Code:2915900090

Physical and Chemical Properties:
Melting point:38ºC
Boiling point:168.8±35.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.327
PSA:37.30000
Exact Mass:242.017776
LogP:2.20

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3261
Packing Group:


Contact us for information like 33FTA chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,4,5,5,6,6,6-Heptafluorohexanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4,5,5,6,6,6-Heptafluorohexanoic acid Use and application,Hexanoic acid, 4,4,5,5,6,6,6-heptafluoro- technical grade,usp/ep/jp grade.


Related News: He also mentioned that derivatives of these APIs and lot of other value-added APIs in the same range will also be manufactured at the new facility. 10-(11,23,31-trioxidaneyl)-13,23,3a14,33,3a4,43,5a14,53,5a4,63,73,83,8a4,93,10a4-pentadecaoxapyrene manufacturers Founded outside Venice in 1949 as a maker of glass bottles for wine and perfume, the firm shifted to glass packaging for the pharmaceutical sector in the early 1970s and later grew to become a leading player in the industry, expanding overseas with new factories in Mexico in 2007 and China in 2012. C-(3-methoxy-phenyl)-N,N’-bis-(3-phenyl-[1,2,4]thiadiazol-5-yl)-methanediamine suppliers Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. (2S,3R)-2-(but-3-en-1-yl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-3-hydroxyhex-5-en-1-one vendor & factory.